董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen From | 男 | Chief Executive Officer, Director | 62 | 未披露 | 未持股 | 2025-12-01 |
| Fuad Ahmad | 男 | Director | 55 | 未披露 | 未持股 | 2025-12-01 |
| Adam Sachs | -- | President, Co-Founder, Director | -- | 未披露 | 未持股 | 2025-12-01 |
| Sammy Khalifa | -- | Chief Technology Officer and Director | -- | 未披露 | 未持股 | 2025-12-01 |
| Joseph Doherty | 男 | Director | -- | 未披露 | 未持股 | 2025-12-01 |
| Victoria Carr Brendel | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-01 |
| David D. Ho | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen From | 男 | Chief Executive Officer, Director | 62 | 未披露 | 未持股 | 2025-12-01 |
| Adam Sachs | -- | President, Co-Founder, Director | -- | 未披露 | 未持股 | 2025-12-01 |
| Sarah M. Romano | -- | Chief Financial Officer and Treasurer | -- | 未披露 | 未持股 | 2025-12-01 |
| Sammy Khalifa | -- | Chief Technology Officer and Director | -- | 未披露 | 未持股 | 2025-12-01 |
董事简历
中英对照 | 中文 | 英文- Stephen From
-
Stephen From,2022年4月至今担任阿鲁纳生物首席执行官，指导公司战略方向和专有神经外泌体平台的临床推进。从2005年10月到2021年2月，From先生担任总裁兼首席执行官，从2021年2月到2022年1月，担任Kiora Pharmaceuticals, Inc.（前身为EyeGate Pharmaceuticals，Inc.）的执行主席，领导该公司完成了首次公开募股以及眼科治疗领域的多项收购和许可交易。在加入EyeGate之前，From先生曾担任Centelion SAS的首席财务官，该公司当时是赛诺菲安万特的生物技术子公司，并在投资银行工作了几年，在美银证券和Robertson Stephens专注于生命科学领域。From先生拥有西安大略大学的理学学士学位，并获得了Wilfrid Laurier大学的会计学称号。
Stephen From,has served as Chief Executive Officer of Aruna Bio from April 2022 through the present, guiding the company's strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and Chief Executive Officer, and from February 2021 through January 2022 served as Executive Chairman, of Kiora Pharmaceuticals, Inc., formerly known as EyeGate Pharmaceuticals, Inc., leading the company through its initial public offering and multiple acquisitions and licensing transactions in the ophthalmic therapeutics space. Prior to EyeGate, Mr. From served as the Chief Financial Officer of Centelion SAS, then a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University. - Stephen From,2022年4月至今担任阿鲁纳生物首席执行官，指导公司战略方向和专有神经外泌体平台的临床推进。从2005年10月到2021年2月，From先生担任总裁兼首席执行官，从2021年2月到2022年1月，担任Kiora Pharmaceuticals, Inc.（前身为EyeGate Pharmaceuticals，Inc.）的执行主席，领导该公司完成了首次公开募股以及眼科治疗领域的多项收购和许可交易。在加入EyeGate之前，From先生曾担任Centelion SAS的首席财务官，该公司当时是赛诺菲安万特的生物技术子公司，并在投资银行工作了几年，在美银证券和Robertson Stephens专注于生命科学领域。From先生拥有西安大略大学的理学学士学位，并获得了Wilfrid Laurier大学的会计学称号。
- Stephen From,has served as Chief Executive Officer of Aruna Bio from April 2022 through the present, guiding the company's strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and Chief Executive Officer, and from February 2021 through January 2022 served as Executive Chairman, of Kiora Pharmaceuticals, Inc., formerly known as EyeGate Pharmaceuticals, Inc., leading the company through its initial public offering and multiple acquisitions and licensing transactions in the ophthalmic therapeutics space. Prior to EyeGate, Mr. From served as the Chief Financial Officer of Centelion SAS, then a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University.
- Fuad Ahmad
-
Fuad Ahmad，自2023年1月起担任Mitek系统公司临时首席财务官。Ahmad先生自2013年1月以来一直是FLG Partners的合伙人，并担任FLG Partners多个客户的咨询首席财务官。Ahmad先生于2022年5月至12月担任Vaxart公司临时首席财务官，该公司是一家专注于口服重组疫苗的发现、开发和商业化的生物技术公司。在此之前，Ahmad先生曾担任IRIDEX公司的临时首席财务官。IRIDEX公司是一家眼科医疗技术公司，专注于突破性产品和程序的开发和商业化。Mitek系统公司致力于治疗威胁视力的眼部疾病，Chargebee公司是一个订阅管理/计费自动化SaaS平台。2019年11月至2020年8月，Ahmad先生担任Cutera, Inc.的临时首席财务官。此前，从2018年10月至2019年11月，Ahmad先生在FLG Partners担任Telenav, Inc.的首席财务官，该公司以前是一家上市的企业软件公司，专注于联网护理和基于位置的服务。2016年4月至2018年6月，Ahmad先生担任Quantum Corporation的首席财务官，该公司是一家上市公司，专注于企业数据存储和软件定义的存储工作流程。从2015年11月到2016年3月，艾哈迈德在私营企业物联网软件公司Real Time Innovation，Inc.的FLG合作伙伴项目中任职。在Real Time Innovation，艾哈迈德担任董事会顾问和首席执行官，公司将业务转变为订阅定价。在Real Time Innovation之前，Ahmad先生从2013年2月至2015年11月在FLG Partners担任Ensighten，Inc.的首席财务官。从1996年6月至2012年4月，Ahmad先生在公共和私营公司担任过各种职务。艾哈迈德先生在杨百翰大学获得金融学士学位。
Fuad Ahmad,has served as Mitek Systems, Inc. interim Chief Financial Officer since January 2023. Mr. Ahmad has been a partner at FLG Partners since January 2013 and has served as consulting Chief Financial Officer for multiple clients of FLG Partners. Mr. Ahmad has served as the Interim Chief Financial Officer of Vaxart Inc., a biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines from May through December 2022. Prior to that Mr. Ahmad served as the Interim Chief Financial Officer of IRIDEX Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures Mitek Systems, Inc. ed to treat sight-threatening eye conditions and Chargebee Inc., a subscription management/billing automation SaaS platform. From November 2019 to August 2020, Mr. Ahmad served as Interim Chief Financial Officer of Cutera, Inc. Previously, from October 2018 to November 2019, Mr. Ahmad served on an FLG Partners assignment as Chief Financial Officer of Telenav, Inc., a formerly listed enterprise software company focused on connected care and location-based services. From April 2016 to June 2018, Mr. Ahmad served as Chief Financial Officer of Quantum Corporation, a listed company focused on enterprise data storage and software defined storage workflows. From November 2015 to March 2016, Mr. Ahmad served on an FLG Partners assignment for Real Time Innovation, Inc., a private enterprise IoT software company. At Real Time Innovation, Mr. Ahmad served as an advisor to the board of directors and the chief executive officer as the company transitioned the business to subscription pricing. Prior to Real Time Innovation, Mr. Ahmad served on an FLG Partners assignment as Chief Financial Officer for Ensighten, Inc. from February 2013 until November 2015. From June 1996 to April 2012, Mr. Ahmad served in various positions with both public and private companies. Mr. Ahmad received a B.S. in Finance from Brigham Young University. - Fuad Ahmad，自2023年1月起担任Mitek系统公司临时首席财务官。Ahmad先生自2013年1月以来一直是FLG Partners的合伙人，并担任FLG Partners多个客户的咨询首席财务官。Ahmad先生于2022年5月至12月担任Vaxart公司临时首席财务官，该公司是一家专注于口服重组疫苗的发现、开发和商业化的生物技术公司。在此之前，Ahmad先生曾担任IRIDEX公司的临时首席财务官。IRIDEX公司是一家眼科医疗技术公司，专注于突破性产品和程序的开发和商业化。Mitek系统公司致力于治疗威胁视力的眼部疾病，Chargebee公司是一个订阅管理/计费自动化SaaS平台。2019年11月至2020年8月，Ahmad先生担任Cutera, Inc.的临时首席财务官。此前，从2018年10月至2019年11月，Ahmad先生在FLG Partners担任Telenav, Inc.的首席财务官，该公司以前是一家上市的企业软件公司，专注于联网护理和基于位置的服务。2016年4月至2018年6月，Ahmad先生担任Quantum Corporation的首席财务官，该公司是一家上市公司，专注于企业数据存储和软件定义的存储工作流程。从2015年11月到2016年3月，艾哈迈德在私营企业物联网软件公司Real Time Innovation，Inc.的FLG合作伙伴项目中任职。在Real Time Innovation，艾哈迈德担任董事会顾问和首席执行官，公司将业务转变为订阅定价。在Real Time Innovation之前，Ahmad先生从2013年2月至2015年11月在FLG Partners担任Ensighten，Inc.的首席财务官。从1996年6月至2012年4月，Ahmad先生在公共和私营公司担任过各种职务。艾哈迈德先生在杨百翰大学获得金融学士学位。
- Fuad Ahmad,has served as Mitek Systems, Inc. interim Chief Financial Officer since January 2023. Mr. Ahmad has been a partner at FLG Partners since January 2013 and has served as consulting Chief Financial Officer for multiple clients of FLG Partners. Mr. Ahmad has served as the Interim Chief Financial Officer of Vaxart Inc., a biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines from May through December 2022. Prior to that Mr. Ahmad served as the Interim Chief Financial Officer of IRIDEX Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures Mitek Systems, Inc. ed to treat sight-threatening eye conditions and Chargebee Inc., a subscription management/billing automation SaaS platform. From November 2019 to August 2020, Mr. Ahmad served as Interim Chief Financial Officer of Cutera, Inc. Previously, from October 2018 to November 2019, Mr. Ahmad served on an FLG Partners assignment as Chief Financial Officer of Telenav, Inc., a formerly listed enterprise software company focused on connected care and location-based services. From April 2016 to June 2018, Mr. Ahmad served as Chief Financial Officer of Quantum Corporation, a listed company focused on enterprise data storage and software defined storage workflows. From November 2015 to March 2016, Mr. Ahmad served on an FLG Partners assignment for Real Time Innovation, Inc., a private enterprise IoT software company. At Real Time Innovation, Mr. Ahmad served as an advisor to the board of directors and the chief executive officer as the company transitioned the business to subscription pricing. Prior to Real Time Innovation, Mr. Ahmad served on an FLG Partners assignment as Chief Financial Officer for Ensighten, Inc. from February 2013 until November 2015. From June 1996 to April 2012, Mr. Ahmad served in various positions with both public and private companies. Mr. Ahmad received a B.S. in Finance from Brigham Young University.
- Adam Sachs
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Sammy Khalifa
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Joseph Doherty
-
Joseph Doherty，自2025年1月起担任伍斯特市校园公司的首席执行官，该公司是一家非营利公司，其基本公司宗旨是培育、促进和支持马萨诸塞大学。自2020年以来，Doherty先生一直担任圣约翰高中的教师，自2022年3月以来，Doherty先生还担任Immertec的董事会成员，该公司是一家为医疗保健培训创造沉浸式互动体验的软件公司。2021年至2025年，他担任马萨诸塞州生物医学倡议（MBI）的BOLT倡议主任，这是一家非营利性生命科学创业孵化器。2019年1月至2020年8月，他担任Scapa Healthcare总裁，2019年1月至2020年5月，他是伦敦证券交易所有限公司市场AIM上市公司Scapa Group的董事会成员。在那里，他监督了一家B2B企业，专注于为全球市场领导者开发和制造医疗设备和消费者健康产品。从2015年到2019年，Doherty先生担任了越来越多的职责，包括担任奥林巴斯手术技术美国公司的总裁，该公司是美洲奥林巴斯公司的一家医疗设备子公司。他还曾在强生（NYSE：JNJ）工作了超过24年，并担任过各种职责，职责越来越重，最终担任负责整合和转型的副总裁。Doherty先生获得了美国西点军校的工程学理学学士学位和尼科尔斯学院的工商管理硕士学位。
Joseph Doherty,has served as CEO of the Worcester City Campus Corporation, a not-for-profit corporation whose base corporate purpose is to foster, promote and support the University of Massachusetts since January 2025. Since 2020, Mr. Doherty has served as a teacher at Saint John's High School, and since March 2022, Mr. Doherty has also served as a member of the board of directors of Immertec, a software company that creates immersive and interactive experiences for training in healthcare. From 2021 to 2025, he served as the Director for the BOLT initiative at the Massachusetts Biomedical Initiative (MBI), a nonprofit life science startup incubator. From January 2019 to August 2020, he served as the President of Scapa Healthcare, and from January 2019 to May 2020, he was a member of the board of directors of Scapa Group, a publicly traded company on AIM, a market of the London Stock Exchange plc. There, he oversaw a B2B business focused on developing and manufacturing medical devices and consumer wellness products for global market leaders. From 2015 to 2019, Mr. Doherty served in roles of increasing responsibility, including as President of Olympus Surgical Technologies America, a medical device subsidiary of Olympus Corporation of the Americas. He also spent over 24 years with Johnson & Johnson (NYSE: JNJ) and held various roles with increasing responsibilities, ultimately serving as the Vice President of Integration and Transformation. Mr. Doherty received a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College. - Joseph Doherty，自2025年1月起担任伍斯特市校园公司的首席执行官，该公司是一家非营利公司，其基本公司宗旨是培育、促进和支持马萨诸塞大学。自2020年以来，Doherty先生一直担任圣约翰高中的教师，自2022年3月以来，Doherty先生还担任Immertec的董事会成员，该公司是一家为医疗保健培训创造沉浸式互动体验的软件公司。2021年至2025年，他担任马萨诸塞州生物医学倡议（MBI）的BOLT倡议主任，这是一家非营利性生命科学创业孵化器。2019年1月至2020年8月，他担任Scapa Healthcare总裁，2019年1月至2020年5月，他是伦敦证券交易所有限公司市场AIM上市公司Scapa Group的董事会成员。在那里，他监督了一家B2B企业，专注于为全球市场领导者开发和制造医疗设备和消费者健康产品。从2015年到2019年，Doherty先生担任了越来越多的职责，包括担任奥林巴斯手术技术美国公司的总裁，该公司是美洲奥林巴斯公司的一家医疗设备子公司。他还曾在强生（NYSE：JNJ）工作了超过24年，并担任过各种职责，职责越来越重，最终担任负责整合和转型的副总裁。Doherty先生获得了美国西点军校的工程学理学学士学位和尼科尔斯学院的工商管理硕士学位。
- Joseph Doherty,has served as CEO of the Worcester City Campus Corporation, a not-for-profit corporation whose base corporate purpose is to foster, promote and support the University of Massachusetts since January 2025. Since 2020, Mr. Doherty has served as a teacher at Saint John's High School, and since March 2022, Mr. Doherty has also served as a member of the board of directors of Immertec, a software company that creates immersive and interactive experiences for training in healthcare. From 2021 to 2025, he served as the Director for the BOLT initiative at the Massachusetts Biomedical Initiative (MBI), a nonprofit life science startup incubator. From January 2019 to August 2020, he served as the President of Scapa Healthcare, and from January 2019 to May 2020, he was a member of the board of directors of Scapa Group, a publicly traded company on AIM, a market of the London Stock Exchange plc. There, he oversaw a B2B business focused on developing and manufacturing medical devices and consumer wellness products for global market leaders. From 2015 to 2019, Mr. Doherty served in roles of increasing responsibility, including as President of Olympus Surgical Technologies America, a medical device subsidiary of Olympus Corporation of the Americas. He also spent over 24 years with Johnson & Johnson (NYSE: JNJ) and held various roles with increasing responsibilities, ultimately serving as the Vice President of Integration and Transformation. Mr. Doherty received a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College.
- Victoria Carr Brendel
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- David D. Ho
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Stephen From
Stephen From,2022年4月至今担任阿鲁纳生物首席执行官，指导公司战略方向和专有神经外泌体平台的临床推进。从2005年10月到2021年2月，From先生担任总裁兼首席执行官，从2021年2月到2022年1月，担任Kiora Pharmaceuticals, Inc.（前身为EyeGate Pharmaceuticals，Inc.）的执行主席，领导该公司完成了首次公开募股以及眼科治疗领域的多项收购和许可交易。在加入EyeGate之前，From先生曾担任Centelion SAS的首席财务官，该公司当时是赛诺菲安万特的生物技术子公司，并在投资银行工作了几年，在美银证券和Robertson Stephens专注于生命科学领域。From先生拥有西安大略大学的理学学士学位，并获得了Wilfrid Laurier大学的会计学称号。
Stephen From,has served as Chief Executive Officer of Aruna Bio from April 2022 through the present, guiding the company's strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and Chief Executive Officer, and from February 2021 through January 2022 served as Executive Chairman, of Kiora Pharmaceuticals, Inc., formerly known as EyeGate Pharmaceuticals, Inc., leading the company through its initial public offering and multiple acquisitions and licensing transactions in the ophthalmic therapeutics space. Prior to EyeGate, Mr. From served as the Chief Financial Officer of Centelion SAS, then a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University.- Stephen From,2022年4月至今担任阿鲁纳生物首席执行官，指导公司战略方向和专有神经外泌体平台的临床推进。从2005年10月到2021年2月，From先生担任总裁兼首席执行官，从2021年2月到2022年1月，担任Kiora Pharmaceuticals, Inc.（前身为EyeGate Pharmaceuticals，Inc.）的执行主席，领导该公司完成了首次公开募股以及眼科治疗领域的多项收购和许可交易。在加入EyeGate之前，From先生曾担任Centelion SAS的首席财务官，该公司当时是赛诺菲安万特的生物技术子公司，并在投资银行工作了几年，在美银证券和Robertson Stephens专注于生命科学领域。From先生拥有西安大略大学的理学学士学位，并获得了Wilfrid Laurier大学的会计学称号。
- Stephen From,has served as Chief Executive Officer of Aruna Bio from April 2022 through the present, guiding the company's strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and Chief Executive Officer, and from February 2021 through January 2022 served as Executive Chairman, of Kiora Pharmaceuticals, Inc., formerly known as EyeGate Pharmaceuticals, Inc., leading the company through its initial public offering and multiple acquisitions and licensing transactions in the ophthalmic therapeutics space. Prior to EyeGate, Mr. From served as the Chief Financial Officer of Centelion SAS, then a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University.
- Adam Sachs
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Sarah M. Romano
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Sammy Khalifa
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介